Verve Therapeutics, Inc. (NASDAQ:VERV - Get Free Report)'s stock price was up 6.7% during trading on Wednesday . The company traded as high as $8.58 and last traded at $8.60. Approximately 392,140 shares traded hands during trading, a decline of 76% from the average daily volume of 1,661,113 shares. The stock had previously closed at $8.06.
Analyst Ratings Changes
A number of brokerages recently weighed in on VERV. HC Wainwright lowered their price target on shares of Verve Therapeutics from $15.00 to $14.00 and set a "buy" rating for the company in a report on Wednesday, November 6th. Canaccord Genuity Group lifted their target price on Verve Therapeutics from $29.00 to $32.00 and gave the company a "buy" rating in a research note on Wednesday, November 6th. Finally, Royal Bank of Canada dropped their target price on Verve Therapeutics from $20.00 to $17.00 and set an "outperform" rating for the company in a research report on Wednesday, November 6th.
Get Our Latest Analysis on VERV
Verve Therapeutics Price Performance
The stock has a 50 day moving average price of $6.50 and a two-hundred day moving average price of $5.87.
Hedge Funds Weigh In On Verve Therapeutics
Institutional investors have recently modified their holdings of the stock. GAMMA Investing LLC raised its position in shares of Verve Therapeutics by 189.7% in the 4th quarter. GAMMA Investing LLC now owns 6,054 shares of the company's stock valued at $34,000 after acquiring an additional 3,964 shares during the period. IFP Advisors Inc grew its stake in Verve Therapeutics by 823,700.0% in the fourth quarter. IFP Advisors Inc now owns 8,238 shares of the company's stock valued at $47,000 after acquiring an additional 8,237 shares during the period. Creative Planning bought a new stake in shares of Verve Therapeutics in the third quarter worth about $50,000. PFG Investments LLC acquired a new stake in Verve Therapeutics during the 3rd quarter worth approximately $53,000. Finally, Erste Asset Management GmbH acquired a new stake in shares of Verve Therapeutics during the third quarter worth $56,000. 97.11% of the stock is currently owned by institutional investors and hedge funds.
Verve Therapeutics Company Profile
(
Get Free Report)
Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.
See Also
Before you consider Verve Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Verve Therapeutics wasn't on the list.
While Verve Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
